KRAS G12C in NSCLC: An In-depth Look
You've probably wondered about the KRAS G12C mutation, known for being the most prevalent in non-small cell lung cancer (NSCLC). Want to learn more about it and understand its impact on patient outcomes?
Our detailed document covers this topic, offering valuable insights into the challenges of treating NSCLC associated with this mutation and the role of KRAS proteins. You're invited to read and leverage these insights to improve patient care practices.
Mirati Therapeutics
